A recent study has found that the first HPV (human papillomavirus) vaccine developed in China, Cecolin, can offer female adults full immunity against two types of the virus.

Cecolin was jointly developed by Xiamen University and Xiamen Innovax, making China the third country in the world to attain an independent cervical cancer vaccine supply after the U.S. and the UK. It earned World Health Organization Prequalification in October 2021.

In the study, a group of Chinese researchers analyzed data from 66 months of follow-up visits as a part of the bivalent vaccine's Phase 3 clinical trial, and found that its efficacy against high-grade genital lesions, typical symptoms of cervical cancer, reached 100 percent.

Furthermore, the E coli-produced HPV 16/18 recombinant vaccine realized 97-percent efficacy against persistent HPV infections, according to the study published in the journal Lancet Infectious Diseases on August 26, 2022. 

The clinical trial included 7,372 healthy women aged 18 to 45, with 3,689 in the vaccinated group and 3,683 in the control group. The cumulative incidence in the vaccinated group was noticeably lower than that in the control group, according to the study.

(With input from Xinhua)